Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults

What Was Tested

This registered not phased trial tested NAD+.

Nicotinamide adenine dinucleotide (NAD) is a coenzyme playing a central role in human metabolic pathways.

NAD precursors exist in multiple forms.

It had four arms (groups): Nicotinamide (NAM) (experimental), Nicotinamide Riboside (NR) (experimental), Nicotinamide Mono Nucleotide (NMN) (experimental) and Microcrystalline cellulose (placebo comparator).

The registry classes the interventions as dietary supplement.

Who Took Part

The registry lists 68 actual participants took part.

It was open to people of any sex aged from 18 years up to 50 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Healthy male and female aged 18-50 years, inclusive, at enrolment. Body mass index (BMI) between 18.5 to 27.0 kg/m². Able to understand and to sign a written informed consent prior to study enrolment. Willing and able to comply with the requirements for participation in this study.

The full record lists 4 inclusion and 12 exclusion criteria; among the exclusions: known history of allergy or intolerance to the investigational products; current smoker (e.g., cigarette, tobacco, cannabis) who exceeds 5 cigarettes per week; currently participating in another research study.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

The NAD+ group and the comparison group ran side by side rather than switching.

Being open-label, the NAD+ study did not mask who received what.

It started in 2022-07-12 with completion listed for 2022-11-24.

It ran at 1 site in Switzerland.

Its stated primary purpose is basic science.

What Was Measured

It also tracked 2 secondary outcomes, for example Determine the extent the NAD+ precursors(NAM, NR and NMN) affect the NAD metabolome in whole blood compared to placebo and Compare the extent the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in whole blood.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 68 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.